Volume 63, Issue 6, Pages (June 2003)

Slides:



Advertisements
Similar presentations
Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages
Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Management of IgA nephropathy: Evidence-based recommendations
Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.
Volume 54, Issue 2, Pages (August 1998)
Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.
Volume 84, Issue 2, Pages (August 2013)
Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction 
Viper venom for diabetic nephropathy
Thinking Beyond New Clinical Guidelines: Update in Hypertension
Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani 
Membranous nephropathy: When and how to treat
Viper venom for diabetic nephropathy
Volume 54, Issue 2, Pages (August 1998)
Renoprotective effects of vitamin D analogs
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 63, Issue 3, Pages (March 2003)
Volume 80, Issue 9, Pages (November 2011)
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,
Is there a pharmacologic basis for combination renin axis blockade?
Volume 70, Pages S21-S25 (December 2006)
Volume 57, Pages S32-S37 (April 2000)
Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients  Roberto.
Volume 64, Issue 5, Pages (November 2003)
Steven J. Rosansky, Richard J. Glassock  Kidney International 
Volume 74, Issue 3, Pages (August 2008)
Body weight is a fluctuating parameter in hemodialysis patients
Volume 72, Issue 12, Pages (December 2007)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Prediabetes as a Precursor to Diabetic Kidney Disease
Volume 71, Issue 11, Pages (June 2007)
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease  S. Bianchi, R. Bigazzi, V.M. Campese 
Volume 68, Issue 6, Pages (December 2005)
Blood pressure targets in hemodialysis patients
Volume 69, Issue 12, Pages (June 2006)
Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect?  Areef Ishani, Charles A. Herzog,
David M. Charytan, John P. Forman  Kidney International 
Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen  David I. Ortiz-Melo, Robert F. Spurney 
Volume 67, Issue 1, Pages (January 2005)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
The future of renoprotection: Frustration and promises
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Volume 56, Issue 2, Pages (August 1999)
Volume 67, Pages S52-S54 (January 2005)
Counteracting progression of renal disease: A look into the future
Nephrology Crossword: Glomerulonephritis
Volume 58, Issue 5, Pages (November 2000)
Volume 82, Issue 9, Pages (November 2012)
Volume 54, Issue 5, Pages (November 1998)
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Carmine Zoccali, Francesca Mallamaci  Kidney International 
Volume 73, Issue 5, Pages (March 2008)
Volume 55, Pages S3-S16 (June 1999)
The Danish Renal Biopsy Register
Volume 68, Issue 5, Pages (November 2005)
Volume 57, Issue 3, Pages (March 2000)
Volume 64, Issue 4, Pages (October 2003)
Volume 61, Issue 2, Pages (February 2002)
Volume 62, Pages S36-S41 (December 2002)
Volume 70, Issue 5, Pages (September 2006)
Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti 
Arya M. Sharma, Joachim Beige, Armin Distler  Kidney International 
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications 
Volume 55, Pages S41-S46 (June 1999)
Lipoprotein abnormalities in diabetic nephropathy
Proteinuria and hypertension with tyrosine kinase inhibitors
Volume 71, Issue 3, Pages (February 2007)
Antonio Piccoli, Luana Pillon  Kidney International 
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

Volume 63, Issue 6, Pages 2214-2221 (June 2003) Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis  Carmela Iodice, Mario M. Balletta, Roberto Minutolo, Paolo Giannattasio, Stefano Tuccillo, Vincenzo Bellizzi, Maurizio D'Amora, Giorgio Rinaldi, Giuseppe Signoriello, Giuseppe Conte, Luca De Nicola  Kidney International  Volume 63, Issue 6, Pages 2214-2221 (June 2003) DOI: 10.1046/j.1523-1755.2003.00015.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Study design. Angiotensin-converting enzyme inhibitor (ACE-I) was ramipril and angiotensin II AT1 receptor (ARA) was irbesartan. The doses of the two agents were given in doses of mg/day. Basal evaluation was performed at time 0. Kidney International 2003 63, 2214-2221DOI: (10.1046/j.1523-1755.2003.00015.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Effect of increasing ramipril dose, combined therapy, and irbesartan alone on proteinuria and α1microglobulin (α1m) in ten patients with nonproliferative glomerulonephritis (NPGN). Data are mean ± SD. aP < 0.05 for angiotensin-converting enzyme inhibitor (ACE-I) vs. pretreatment values; bP < 0.05 for dose effect of ACE-I; cP < 0.05 for angiotensin II AT1 receptor (ARA) vs. pretreatment values; dP < 0.05 for ACE-I + ARA vs. pretreatment values; eP < 0.05 for differences among treatment arms. Kidney International 2003 63, 2214-2221DOI: (10.1046/j.1523-1755.2003.00015.x) Copyright © 2003 International Society of Nephrology Terms and Conditions